116 related articles for article (PubMed ID: 2784721)
1. Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell lines resistant to antitumor agents.
Allavena P; Damia G; Colombo T; Maggioni D; D'Incalci M; Mantovani A
Cell Immunol; 1989 Apr; 120(1):250-8. PubMed ID: 2784721
[TBL] [Abstract][Full Text] [Related]
2. Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis.
Harker WG; Tom C; McGregor JR; Slade L; Samlowski WE
Cancer Res; 1990 Sep; 50(18):5931-6. PubMed ID: 1975512
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma.
Savas B; Cole SP; Tsuruo T; Pross HF
J Clin Immunol; 1996 Nov; 16(6):348-57. PubMed ID: 8946280
[TBL] [Abstract][Full Text] [Related]
4. Susceptibility of human and murine drug-resistant tumor cells to the lytic activity of rIL2-activated lymphocytes (LAK).
Gambacorti-Passerini C; Rivoltini L; Radrizzani M; Supino R; Mariani M; Parmiani G
Cancer Metastasis Rev; 1988 Dec; 7(4):335-45. PubMed ID: 3061677
[TBL] [Abstract][Full Text] [Related]
5. Human tumor cell lines with pleiotropic drug resistance are efficiently killed by interleukin-2 activated killer cells and by activated monocytes.
Allavena P; Grandi M; D'Incalci M; Geri O; Giuliani FC; Mantovani A
Int J Cancer; 1987 Jul; 40(1):104-7. PubMed ID: 3496283
[TBL] [Abstract][Full Text] [Related]
6. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines.
Treichel RS; Olken S
Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437
[TBL] [Abstract][Full Text] [Related]
7. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
8. Hierarchy of in vitro sensitivity and resistance of tumor cells to cytotoxic effector cells, cytokines, drugs and toxins.
Safrit JT; Bonavida B
Cancer Immunol Immunother; 1992; 34(5):321-8. PubMed ID: 1540978
[TBL] [Abstract][Full Text] [Related]
9. Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistance.
Rivoltini L; Gambacorti-Passerini C; Supino R; Parmiani G
Int J Cancer; 1989 May; 43(5):880-5. PubMed ID: 2714894
[TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
11. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.
Rosenstein M; Yron I; Kaufmann Y; Rosenberg SA
Cancer Res; 1984 May; 44(5):1946-53. PubMed ID: 6608989
[TBL] [Abstract][Full Text] [Related]
12. [Low susceptibility of choriocarcinoma cell lines to lymphokine activated killer (LAK) cells].
Kameda T; Negoro T; Hagiwara M; Koyama M; Matsuzaki N; Saji F; Tanizawa O
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan; 41(1):1-6. PubMed ID: 2784473
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
Nio Y; Zighelboim J; Berek JS; Bonavida B
Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of colony formation of drug-resistant human tumor cell lines by combinations of interleukin-2-activated killer cells and antitumor drugs.
Ohtsu A; Sasaki Y; Tamura T; Fujiwara Y; Ohe Y; Minato K; Nakagawa K; Bungo M; Saijo N
Jpn J Cancer Res; 1989 Mar; 80(3):265-70. PubMed ID: 2498260
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of chemoresistant murine and human tumor cells to lysis by interleukin 2-activated lymphocytes.
Gambacorti-Passerini C; Rivoltini L; Supino R; Rodolfo M; Radrizzani M; Fossati G; Parmiani G
Cancer Res; 1988 May; 48(9):2372-6. PubMed ID: 3258541
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK- and LAK-mediated cytotoxicity.
Scheper RJ; Dalton WS; Grogan TM; Schlosser A; Bellamy WT; Taylor CW; Scuderi P; Spier C
Int J Cancer; 1991 Jun; 48(4):562-7. PubMed ID: 1710609
[TBL] [Abstract][Full Text] [Related]
18. Human oncogene-transfected tumor cells display differential susceptibility to lysis by lymphokine-activated killer cells (LAK) and natural killer cells.
Lanza LA; Wilson DJ; Ikejiri B; Roth JA; Grimm EA
J Immunol; 1986 Oct; 137(8):2716-20. PubMed ID: 3489774
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of lymphokine-activated killer cell cytotoxicity by monoclonal antibodies against human small cell lung carcinoma.
Tong AW; Lee JC; Wang RM; Ordonez G; Stone MJ
Cancer Res; 1989 Aug; 49(15):4103-8. PubMed ID: 2545333
[TBL] [Abstract][Full Text] [Related]
20. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]